Homocysteine Reduction Infusion

Elevated homocysteine is a recognised risk factor for cardiovascular disease, stroke, and cognitive decline. IVC Olomouc offers a targeted 500 Kč infusion containing a B-vitamin complex — typically B6, B9 (folate), and B12 — to support the body's methylation pathways that convert homocysteine back to methionine and cysteine. Unlike oral B-vitamin supplements, the intravenous route ensures rapid delivery and full availability to tissues where methylation enzymes operate, making it an effective adjunct for patients with known hyperhomocysteinaemia.

Homocysteine is a sulphur-containing amino acid produced as a byproduct of methionine metabolism. In normal physiology, it is recycled efficiently via two routes: remethylation (which requires folate and vitamin B12) and transsulphuration (which requires vitamin B6). When these pathways are impaired — due to genetic variants such as MTHFR mutations, dietary B-vitamin deficiencies, or high methionine intake — homocysteine accumulates in plasma, where it damages endothelial cells, promotes platelet aggregation, and contributes to atherosclerosis. Epidemiological data consistently associate elevated homocysteine (above 15 μmol/L) with increased risk of heart attack, stroke, and dementia. The homocysteine reduction infusion at IVC Olomouc addresses this through high-dose intravenous delivery of the three B-vitamins central to homocysteine metabolism: pyridoxine (B6), methylfolate or folic acid (B9), and cyanocobalamin or methylcobalamin (B12). By bypassing gut absorption, the infusion achieves plasma concentrations of these cofactors that are difficult to reach with oral supplements, particularly in patients with low stomach acid, gastrointestinal inflammation, or the common MTHFR C677T variant that impairs folate processing. The session runs approximately 40–45 minutes via peripheral IV. It is particularly relevant for patients with a blood test showing elevated homocysteine, those with a family history of early cardiovascular disease, people following plant-based diets (at risk for B12 deficiency), and individuals already taking oral B vitamins without achieving normalisation. The practitioner may recommend periodic retesting to track homocysteine levels and adjust treatment frequency accordingly.